Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 4/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL685487 | 0.95 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085060 | 0.94 | CRHR1 (0.36) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10089868 | 0.93 | NTRK1 (0.36) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10089957 | 0.92 | CRHR1 (0.35) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10089845 | 0.91 | NTRK1 (0.34) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10089471 | 0.91 | DRD4 (0.42) | — | |
| SCHEMBL10089862 | 0.91 | DGAT2 (0.36) | CRHR1NTRK1 | |
| SCHEMBL13085405 | 0.90 | CRHR1 (0.37) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL686481 | 0.90 | CRHR1 (0.36) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085179 | 0.90 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | SSTR4 3131/4885CRHR1 3984/4885MAPK14 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.